Status unknownNCT03176342Updated Jun 6, 2017

Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)

An interventional study of patch test in Drug Reaction, sponsored by Chulalongkorn University. Status unknown at 1 site in Thailand. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Chulalongkorn University · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Jun 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

Registered 9 months after the study started (first participant enrolled Aug 2016, registered Jun 2017).

Phase: Not applicable
Study type: Interventional
Enrollment: 30
Allocation: Not applicable
Ages: 18 Years and older
Sex: All

Study summary

The study is about drug patch tests in patients who have history of severe cutaneous drug reaction including Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug-induced eosinophilia and systemic symptoms (DRESS), AGEP (Acute generalized exanthematous pustulosis) and generalized bullous fixed drug eruptions. This study also investigate in Enzyme-linked immunosorbent spot assay (ELIspot) and lymphocyte transformation test. We also trying to prove the correlation among result of drug patch tests, ELIspot and LTT.

Conditions studied

Drug Reaction

Browse trials for

Drug-Related Side Effects and Adverse Reactions 437

Keywords

Drug patch tests

In context

Drug-Related Side Effects and Adverse Reactions

437 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 76 are open to participants now.

This study's planned enrollment of 30 is below the median of 103 across 255 interventional studies indexed under Drug-Related Side Effects and Adverse Reactions.

Lead sponsor

Chulalongkorn University is the lead sponsor of 312 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Patients with history of Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug-induced eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), generalized bullous fixed drug eruption in the past 24 months.
Age more than 18 years old

Exclusion criteria

Exclusion Criteria:

Receiving immunosuppressive drugs or more than 10 mg/day of prednisolone within 1 month.
Pregnancy and lactation

Study design

Phase: Not applicable
Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 30 participants (estimated)

Study arms

Experimental
patch test arm
Patch test by selected allergens and drawing blood for ELIspot and LTT
Other: patch test

Interventions

Otherpatch test
Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
Also known as: Enzyme-linked immunosorbent spot assay (ELIspot) and lymphocyte transformation test (LTT)

What researchers measure

Primary outcomes

Prevalence of positive drug patch test results.
Time frame: 3 years

Secondary outcomes

correlation of drug patch test results, ELIspot and lymphocyte transformation test.
Time frame: 3 years

Study locations

1 of 1 sites recruiting

Division of Dermatology, Faculty of Medicine, Chulalongkorn University
Bangkok, 10330, Thailand
- Pawinee Rerknimitr, MD, MSc · Contact · pawineererk@yahoo.co.th · +6622564253
- Jettanong Klaewsongkram, MD · Sub investigator
- Suwimon Pootongkam, MD, MSc · Sub investigator
- Prattana Sittiwattanawong, MD · Sub investigator
Recruiting

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03176342
Lead sponsor: Chulalongkorn University
Responsible party: Pawinee Rerknimitr (Assistant professor, Chulalongkorn University) — Principal investigator
First posted: Jun 5, 2017
Start date: Aug 4, 2016
Primary completion: Aug 3, 2017 (estimated)
Completion: Aug 3, 2017 (estimated)
Last update: Jun 6, 2017

Oversight

FDA-regulated drug: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Other studies from this sponsor

Chulalongkorn University

Start the discussion